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Phospholamban (PLB). an integlal membrane promin of cardiac sarcoplasmi¢ rettculum (SR}. is dcr, cribed as the reilUlator of the C.aZ'.ATPaz¢ 
pump, via its phosphorylation,,,<lephosphorylation of Scr. 16, Becemly it has been shown that a direct interaction ~w~n the N-terrains! hydrophilk: 
domain or PLB and Ca"'.ATPa~ may be one of the nh-.¢hanisms of regulation, I  order to show that his interaction could be madulated bya 
phosphorylation-indu~d confonnatlonai change [a PLB, we ran CD ltudi=s on the synthetic ~ptide PLB(2-33) in its phospho~lat~ and 
non-phosphowlated form~, at various pHs, concentrations a d in the ub~nc¢ or presence oftrifluor~thanol, The results show a clear difference 
in structure of the phosphorylated an  non.phosphotylated ~ptide, 
Phospholamban; Synthetic i~ptid¢; Phosphorylation: Circular dichroism 
I. INTRODUCTION 
Phospholamban (PLB) is an integral membrane pro. 
rein of cardiac sacroplasmic reticulum (SR) and is 
known to modulate the activity of  the Ca:*-ATPas¢ via 
its phosphorylation bycAMP-dependent protein kinase 
[l,2l, 
It was recently shown, by reconstitution studies, that 
PLB in its dephosphorylated form is an inhibitor of the 
Caa'-ATPase and that its phosphorylation by cAMP- 
PK reverses the inhibition [3-5]. Furthermore, studies 
in the intact heart have shown that fl-adrenergic stimu. 
lation is associated with PLB phosphorylation [6], 
PIB is an amphiphilio polypeptide of 52 amino acids 
and can be divided into two domains: (i) the cytoplasmic 
hydrophilic N-terminal domain which contains Ser-I 6, 
the phosphorylation site for cAMP-PK, and (ii) the hy- 
drophobic C-terminal region that forms an a-helical 
transmembran¢ region. 
Although biochemically well characterized, the me- 
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lecalar mechani,~m by which PLB regulates the Ca='- 
ATPase activity has not yet bccn elucidated. Different 
studies have led to the hypothesis that Ca 2" uptake in 
the SR is modulated by electrostatic nteractions be- 
tween PLB and Ca"'-ATPas¢ [7,8]. More rt~cntly it has 
been shown that a direct interaction between the hydro- 
philic domain of PLB and Ca>-ATPa~ may b¢ one of 
the mechanisms of regulation [5.9,10,11]. Thh interac- 
tion could be modulated by a conforrnational change in 
the hydrophil ic domain of PLB via its phosphorylation, 
as suggested by Hugging et al, [12] when they showed 
that the sensitivity of PLB to digestion by pretenses was 
greatly reduced by phosphorylation. 
In order to obtain direct evidence that phosphoryia- 
tion of Ser-16 of PLB could inda~ a ¢onformational 
change in its hydrophilic domain, w~ ran circular di- 
chroism (CD) studies on the synthetic pcptid¢ PLB(2- 
33) in its phosphorylated and non-phosphorylated 
forms. Our results clearly show that a conformational 
change can be observed upon phosphorylation of the 
peptid¢, 
2, MATERIALS AND METHODS 
2.1. S.vltthesis of PLB(2J3) 
Peptide PLB(2.33) was synthesized manually usinB zolid.phar¢ pep 
tide synthesis, Amino acids were coupled as Bo¢ d=rivativcz (Nc,o=ys- 
tom Laboratories), BOP was ur, cd as the ¢oaplinl| reagent. Synthesis 
was carried out on 4.m=lhyl bcnzhydr~,lamin¢ resin (Applied Biosys- 
terns) to produce the C-terminal amidated pgptid¢. Coupling factions 
wer~ ~fformed in 25% DMF/DCM (v/v) with a three.fold ez~d,,~ of 
prose:ted Boo.amino acids and BOP. in the pre=cnc¢ of DIEA (8 ¢q,), 
Ac~tylation rthe N-terminal r~idue was performed sling a mixture 
of acetic anhydride and DIEA, Cleavage ol'lhe pcptide was perforra~ 
assail the 'low-high' HF procedure, i.e. anhydrous HF in the prcscnc~ 
of dimethyl sulphur, p.cresol and thiocrmol, 
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2,2, Pucgicatian o/the s~'ntl~e.c prp¢id# 
The crude synthetic pcptidc w~s fractionatcd on a Frac|oli¢l TSK 
HW.40 (F~ (Merck) column usin~ i0~ aoctic acid as elucnt, Fractions 
conlaininl~ the p~ptide were pooled, lynphilizcd and purified by H PLC 
on a Waters A.~o¢in~es System, Absorbance was monitored at 20fi am. 
A Waters PrepPak C8 D¢lat Pak column (300 A, 2S x 100 ram) was 
liradicnt over 20 rain from 20~, CH~CN/0.1~, TFA to 40~ CH~CNI 
0,1% TFA. 
2,3. Phosphur~'latia# of PLIH2-3#) 
Pcptid¢ PLD(2-33) (1 ,S mll~ was phosphorylated using the catalytic 
cubunit of cAMP.protein kinus~ (SilVa) (500 U) in a medium contain. 
ins KCi (0.1 Me, M$CI.. (i raM). EDTA (0,1 raM), Tris (20 raM), ATP 
(10" M) in a total volume of I ml. After incubation at 30'C for I h, 
the reaction was stopp~d by boiling. Pcptid¢ P.PLB(2.33) w:~ purifh~.d 
by HPLC as described for pcptide PLIR2-33). 
2,4, Characwri:atiml of PLB(2.3.~) ttnd P.PLB(2.33J 
Amino acid annl~is ssn~s performed on both pcptides, Alter hydrol. 
ysis with 6 N HCI (I i0*C, 24 h) amino acids were dcrivatizcd with 
phcnylisothiocyanate and anal~cd as d~cribcd by the Waters Picotag 
manual. 
PLB(2.33) and P.PLB(2.33) w~:rc haracterized by measurement of 
their molecular mass by fast atom bombardmenl mass sl',¢ctrometry 
(FAg-MS) pcrl'orraed on a VG Analytical ZAB HF double focusi~8 
mass spectrometer. (i) PLB (2.33), m/z = 3,831,13 (talc, 3,8~1,4S); (it) 
P-PLB(2-33). ~ = 3,91 l.S3 (c~Ic. 3,911,42). 
2,S. Circular dichroism ¢.¢pcrh)#¢nts 
The CD slgctra of both ixptidci were obtained usinl; a Car>, 60 
instrument, ¢alib~ted with d(+)10.cami~hor sulphonic acid. 
Peptid~ were solubilized in phosphate buffer (5 raM), at different 
pHs (4,0, "/.4, 9,0) and in the abscn~ or in the pr©scnec o[" TFE (10, 
I$, 20 and ,1~{;46). Veptid¢ concentrations were determined by amino 
acid analysis. 
The CD data were recorded in a 1 mm quart~c¢ll at 20"C and wcrc 
¢xprc:mcd in terms of eilipticity units per mole of peptid¢ residues (~ 
in dcs.cm:.dmol'~), 
3. RESULTS AND DISCUSSION 
For our study we synthesized peptid¢ PLB(2.33) (Fig. 
1) ac, ctylated as its N.tenninus as native PLB, and ami- 
dated at its C-terminus to avoid artdaecual e ectrostatic 
interactions and also to mimic the hydrophobic charac- 
ter of the C-terminal domain of PLB. The 
phosphorylated peptide was obtained by enzymatic 
phosphorylation with cAMP-PK. 
We then ¢~amin=d the CD spegtra of the 
phosphorylated peptide (P-PLB(2-33)) and non- 
phosphorylatgd pcptid¢ (PLB(2-33)) under various con- 
ditions of pH, concentration and in the presence and 
absence of TFE. Peptid¢ concentrations were deter- 
mined by amino acid analysis. 
The CD spectra of the non-phosphorylated peptide 
(Fig. 2) at a concentration of 5 x 10 "s M in phosphate 
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Fi~. 2. CD spectra of PLB(2-~3) at a concentration f 5 x 10 .) M. in 
phosphate buffer (S raM) nt p[-I 4 (A). pH 7.4 (e} and pH 9.0 (l). The 
data are ~presscd in terms o{" mc=n r~,idu¢ ¢llipticity. ~. in 
dcg.cm-'.dmol "b, 
buffer (5 raM) at different pHs (4.0, 7.4 and 9.0) indi- 
cated the absenc~ of a wcll-d~fined ordered structure, 
No pH-induccd change was obscrv¢d, The broad nega- 
tive shoulder at about 220 nm and the low intensity of 
the negative band at 2(}0 nm suggest that the peptide is 
not completely random, The same results were observed 
for the phosphorylated peptide (data not shown), 
According to secondary structure prediction, several 
groups have suggested a mainly helical structure for the 
hydrophili¢ cytosolic domain of PLB. The first twenty 
residues were predicted to form an ¢~.helical mphipa- 
thic structure, while the followi~lg ten.residue segment 
seemed to be less structured [13,14]. 
To confirm the ¢~istence of the helical structure and 
to compare the conformational behaviour of peplid~ 
PLB(2-33) and P-PLB(2-33), we have examined their 
CD spectra in phosphate butter at pH 7.4 in tl~e pres- 
ence of TFE, as TFE is known to stabilize pre-=xistins 
structures [I 5,15], Th= results are shown in FiB. 3A and 
B. 
The CD spectra nalysis of both pcptides howed that 
increasing amounts of TFE induced a higher a-helical 
content, characterized by the two negative bands at 
about 208 and 220 nm. In 40% TFE. the spectra became 
clearly helical and the negative band at 220 nm r~ched 
- 13. Ix I 03 deg.cm:.dmol') and - 8.9x I0 ~ deg.cm 2,drool" ) 
for the non-phosphorylated and the phosphorylated 
peptid=, respectively. Usin 8 at least-squares curve fit- 
ting procedure for the quantitative analysis of the CD 
spectra [17] it was estimated that the g-helix content at 
40% of, TFE w:s 33% for PL~2-33) a.n.d 25% for P- 
PLB(2-33). These results are in agreement with the pre- 
dicted helical structure for the N-tcrminal domain of 
PLB and also show that the non-phosphorylatcd pep- 
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Fill. 3, CD spot|re of PLC(2-33) (A) and P-PLI3(2.33) (B) at a con=ntration of S x 10 "~ M in pho=phate buff¢r, pH ?.4, containinil 10~t TFE (A). 
15¢l, TFE (el, 20q, TFE (m) arid 40% TFE (e}. 
tide has a more pronounced co-helical character than the 
phosphorylatcd one, 
Comparing the behaviour of both peptid¢, in 15~ 
TFE, monitored by th~ CD c~rv¢ around 200 am, it was 
found that PLB(2-33) was still in a r-.mdom coil confor- 
mation, while P-PLB(2-33) had more structur= (Fig. 4), 
The same results were found with both peptidcs, at a 
five-fold higher concentration, in phosphate buft'¢r 
alone (Fig. 5). 
From these data, it appears that, in the pres=nce of 
TFE, peptides PLB(2-33) and P-PLB(2-33) have differ- 
ent conformational behaviours and that the 
phosphorylatcd peptide adopts an ordered secondary 
structure at a lower concentration of TFE  than the 
non.phosphorylated form, but that the latter is able to 
assume a more co-helical secondary structure, 
The negatively charged phosphate group (pK= = 5.9) 
introduced on Set-16 of PLB(2-33) probably indu¢~ a 
conformational change by electrostatic interactions, 
modifying the intrapeptide hydros.ca bond~. As TFE is 
supposed to lead to an in¢reas¢ of electrostatic interac- 
tions due to tile lowering of the dielectric constant 
[15,16], it is possible that it contributes partly to the 
observed difference in ellipticity between PLB(2-33) and 
P-PLB(2-33). Nevertheless, the CD data, obtained at 
high peptide concentration in the absence of  TFE, con- 
t~rm that phosphorylation of  peptid¢ PLB(2-33) does 
induce a ¢onformational chang¢. 
Simmerman et el. [18], in a study ofdetergcnt-solabii- 
ized PLB, reported that phosphorylation does not sig- 
nificantly alter PLB secondary structure. However. our 
results show a cle=,r difference in structure of the 
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Fill. 4. CO Sl;~:tra of PLB(2-33) (o) and P-PLB(2.33) (el at a concen. 
tration of 5 x 10 -) M in 5 mM phosphate bulTer, pH 7.4, ¢omainlng 
15% TFE. 
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Fig. 5. CD spccira of PLB{2.33) (o) and P-PLi~(2-33} (el at a concen- 
tration of 25 x 10 "~ M in S mM phosphate baiter, pH 7..~. 
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phosphorylated and non-phosphorylated peptide 
PLB(2-33), We suggest, therefore, that such a localized 
conformational change in the cytoplasmic N-terminal 
domain, not detected in secondary structure studies of  
the whole protein, may indeed occur. These results 
would support the hypothesis that PLB regulates, at 
least part l)', the Ca2*-ATPase via its phosphorylation by
direct interaction between the eytosolie part of  both 
proteins. Recently, however, Sasaki e ta l .  [10] have 
shown that PLB suppresses the CaV'-ATPase at two 
different sites, the cytoplasmic domain and the trans- 
membrane domain. They suggested that a conforma- 
tional change of  the PLB transmembrane domain was 
induced by phosphorylation of Set-16 via a conforma- 
tional change of the cytosolie domain. 2H NMR exper- 
iments are now under way to compare the effects of  
PLB and phosphorylated PLB on the lipid bilayer. 
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